3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Neoplasms
13
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
7
Neoplasm Metastasis
6
Melanoma
5
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Leukemia, Myeloid, Acute
3
Solid Tumor
2
Recurrence
2
Prostatic Neoplasms
2
Lung Neoplasms
2
Gastrointestinal Stromal Tumors
2
Colorectal Neoplasms
2
Carcinoma
2
Advanced Solid Tumor
2
Advanced Malignancies
2
cMET-dysregulated Advanced Solid Tumors
1
Urothelial Cancer
1
Thyroid Neoplasms
1
Synovitis, Pigmented Villonodular
1
Solid Tumours
1
Solid Tumour
1
Solid Tumors, KRAS Mutation
1
Solid Tumors
1
Solid Tumor, Adult
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Prostate Cancer Patients
1
Interventions
pembrolizumab
8
Pemetrexed
8
capmatinib
7
Carboplatin
7
ceritinib
5
Cisplatin
5
Bevacizumab
4
Docetaxel
3
trametinib
2
motexafin gadolinium
2
aldesleukin
2
Vinorelbine
2
Paclitaxel
2
Interleukin-2
2
Gefitinib
2
BID protein, human
2
technetium 99m etarfolatide
1
spartalizumab
1
sintilimab
1
satraplatin
1
ribociclib
1
picropodophyllin
1
nazartinib
1
naporafenib
1
milademetan
1
lazertinib
1
fludarabine phosphate
1
fludarabine
1
farletuzumab
1
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Adenocarcinoma of Lung
×
Midazolam
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled